Inozyme Pharma, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
BioMarin Pharmaceutical Inc. has successfully completed its acquisition of Inozyme Pharma, Inc. for $4.00 per share in cash, resulting in Inozyme becoming a wholly-owned subsidiary and its shares being delisted from the Nasdaq Global Select Market.
Inozyme Pharma, Inc. announced the postponement of its 2025 Annual Meeting of Stockholders due to its pending acquisition by BioMarin Pharmaceutical Inc.
Inozyme Pharma, Inc. has approved significant cash transaction bonuses for its Chief Financial Officer and Chief Operating Officer, contingent on their continued employment through the closing of the previously announced merger with BioMarin Pharmaceutical, Inc.
BioMarin is set to acquire Inozyme Pharma in a $270 million deal, adding INZ-701, a Phase 3 enzyme replacement therapy for ENPP1 Deficiency, to its portfolio.
Inozyme Pharma announced positive interim data from its ENERGY 3 trial highlighting INZ-701's potential in treating ENPP1 Deficiency, along with the appointment of Petra Duda as Chief Medical Officer.
Inozyme Pharma is focusing on its ENPP1 Deficiency program, leading to a workforce reduction of approximately 25% and extending its cash runway into the first quarter of 2026.
Inozyme Pharma reports positive interim results for INZ-701 in infants and young children with ENPP1 Deficiency, along with key program updates including completed enrollment in a pivotal trial and regulatory guidance for another.
Inozyme Pharma reported its Q3 2024 financial results, highlighted clinical trial progress, and provided updates on its pipeline, including plans to initiate registrational trials in calciphylaxis and ABCC6 Deficiency in 2025.
Inozyme Pharma's INZ-701 showed positive interim results in a Phase 1 trial, significantly increasing plasma pyrophosphate levels in patients with end-stage kidney disease undergoing hemodialysis.
Inozyme Pharma has appointed Erik Harris, a seasoned biopharmaceutical executive, to its Board of Directors, effective October 3, 2024.
Inozyme Pharma has filed a prospectus supplement to continue its at-the-market offering program, aiming to raise up to an additional $23.8 million.
8-K: Inozyme Pharma Announces Second Quarter 2024 Financial Results and Provides Clinical Program Updates
Inozyme Pharma reported its second quarter 2024 financial results and provided updates on its clinical programs, including expected milestones for its lead candidate INZ-701.
Inozyme Pharma held its annual stockholders meeting on June 18, 2024, where three Class I directors were elected and the appointment of Ernst & Young LLP as the independent auditor was ratified.
Inozyme Pharma announced its first quarter 2024 financial results and provided updates on its clinical programs, including positive data and anticipated milestones.
Inozyme Pharma reports positive topline data from Phase 1/2 trials of INZ-701 in adults with ABCC6 and ENPP1 deficiencies, showing promising safety and efficacy results.
Inozyme Pharma reported its 2023 financial results and provided updates on its clinical programs, including the initiation of a new Phase 1 trial and upcoming topline data readouts.